Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations

Vaccine

Volumn 33, Issue 33, 2015, Pages 4146-4154

  Eidem, Synnøve ^a   Tete, Sarah M ^a,b   Jul Larsen, Åsne ^a   Hoschler, Katja ^c   Montomoli, Emanuele ^d   Brokstad, Karl A ^a   Cox, Rebecca J ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Avidity; Healthcare workers; Influenza; Long term antibody persistence; Repeated vaccination

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HEALTH CARE PERSONNEL; HEMOLYSIS ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVACCINATION; SEASONAL INFLUENZA; SEROCONVERSION; SINGLE DRUG DOSE; ANTIBODY AFFINITY; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNODIFFUSION; IMMUNOLOGY; MIDDLE AGED; SERODIAGNOSIS; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; HEALTH PERSONNEL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNODIFFUSION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MIDDLE AGED; NEUTRALIZATION TESTS; YOUNG ADULT;

EID: 84952637482     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.081     Document Type: Article

References (53)

1. World Health Organization Pandemic (H1N1) 2009-update 68 2010, World Health Organization, Available from: http://www.who.int/csr/don/2009_10_02/en/ [cited 2013].
2. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(Jul (5937)):197-201.
3. NIIPH Report of the pandemic 2009 2010, NIIPH, Available from: http://www.fhi.no/eway/default.aspx?pid=239&trg=Content_6496&Main_6157=6261:0:25,6571&MainContent_6261=6496:0:25,6572&Content_6496=6178:83249:25,6572:0:6562:18:::0:0 [cited 2011].
4. Broadbent A.J., Subbarao K. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr Opin Virol 2011, 1(Oct (4)):254-262.
5. Services M.o.H.a.C.H-oO Beredskap mot pandemisk influensa 2013, Services M.o.H.a.C. H-oO, Available from: http://www.regjeringen.no/en/dep/hod/documents/regpubl/stmeld/2012-2013/meld-st-16-20122013.html?id=716183 [cited 2013].
6. Prevention(CDC) CfDCa Selecting viruses for the seasonal influenza vaccine, 2014. Seasonal influenza (Flu) 2014 February 21, 2014 2014, Prevention(CDC) CfDCa, Available from: http://www.cdc.gov/flu/about/season/vaccine-selection.htm [cited 2014 June 06].
7. Gross P.A., Sperber S.J., Donabedian A., Dran S., Morchel G., Cataruozolo P., et al. Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Vaccine 1999, 17(May (18)):2284-2289.
8. Pyhala R., Kumpulainen V., Alanko S., Forsten T. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990-1992. Vaccine 1994, 12(Aug (10)):947-952.
9. Nabeshima S., Kashiwagi K., Murata M., Kanamoto Y., Furusyo N., Hayashi J. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol 2007, 79(3):320-325.
10. de Bruijn I.A., Remarque E.J., Jol-van der Zijde C.M., van Tol M.J., Westendorp R.G., Knook D.L. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999, 179(1):31-36.
11. Beyer W.E., Nauta J.J., Palache A.M., Giezeman K.M., Osterhaus A.D. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 2011, 29(Aug (34)):5785-5792.
12. Beyer W.E., Palache A.M., Sprenger M.J., Hendriksen E., Tukker J.J., Darioli R., et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 1996, 14(Oct (14)):1331-1339.
13. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(Dec (25)):2405-2413.
14. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303(1):37-46.
15. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(Dec (25)):2414-2423.
16. Madhun A.S., Akselsen P.E., Sjursen H., Pedersen G., Svindland S., Nostbakken J.K., et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010, 29(Dec (2)):266-273.
17. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
18. Veguilla V., Hancock K., Schiffer J., Gargiullo P., Lu X., Aranio D., et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011, 49(6):2210-2215.
19. Svindland S.C., Jul-Larsen A., Pathirana R., Andersen S., Madhun A., Montomoli E., et al. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses 2012, 6(Mar (2)):90-100.
20. Schild G.C., Pereira M.S., Chakraverty P. Single-radial-haemolysis: a new method for the assay of antibody to influenza haemagglutinin: applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 1975, 52(1):1.
21. European Agency for the Evaluation of Medicinal Products Note for guidance on harmonization of requirements for influenza vaccines 1997, European Agency for the Evaluation of Medicinal Products, Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf [cited 2012 02/02].
22. Cox R.J., Brokstad K.A., Zuckerman M.A., Wood J.M., Haaheim L.R., Oxford J.S. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994, 12:993.
23. Pedersen G.K., Hoschler K., Oie Solbak S.M., Bredholt G., Pathirana R.D., Afsar A., et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine 2014, 32(Jul (35)):4550-4557.
24. Centers for Disease Control and Prevention Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58(May (19)):521-524.
25. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(Nov (20)):1945-1952.
26. Van Kerkhove M.D., Hirve S., Koukounari A., Mounts A.W. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir Viruses 2013, 7(Sep (5)):872-886. group HNpsw.
27. Khurana S., Verma N., Talaat K.R., Karron R.A., Golding H. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 2012, 205(Feb (4)):610-620.
28. Verma N., Dimitrova M., Carter D.M., Crevar C.J., Ross T.M., Golding H., et al. Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children. J Virol 2012, 86(May (10)):5515-5522.
29. Garcon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012 Mar, 11(3):349-366.
30. Sasaki S., Sullivan M., Narvaez C.F., Holmes T.H., Furman D., Zheng N.Y., et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2011, 121(8):3109.
31. Monsalvo A.C., Batalle J.P., Lopez M.F., Krause J.C., Klemenc J., Hernandez J.Z., et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 2011, 17(2):195-199.
32. Frolich D., Giesecke C., Mei H.E., Reiter K., Daridon C., Lipsky P.E., et al. Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. J Immunol 2010, 185(5):3103-3110.
33. Goldblatt D., Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998, 177(4):1112-1115.
34. Jegaskanda S., Job E.R., Kramski M., Laurie K., Isitman G., de Rose R., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013, 190(4):1837.
35. Co M.D., Cruz J., Takeda A., Ennis F.A., Terajima M. Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals. Hum Vaccines Immunother 2012, 8(9):1218-1222.
36. DiLillo D.J., Tan G.S., Palese P., Ravetch J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 2014, 20(2):143-151.
37. Zhou Y., Ng D.M., Seto W.H., Ip D.K., Kwok H.K., Ma E.S., et al. Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine. PLoS ONE 2011, 6(11):e27169.
38. Igari H., Segawa S., Watanabe A., Suzuki A., Watanabe M., Sakurai T., et al. Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health-care workers of a university hospital in Japan. Microbiol Immunol 2010, 54(10):618-624.
39. Huijskens E., Rossen J., Mulder P., van Beek R., van Vugt H., Verbakel J., et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol 2011, 18(9):1401-1405.
40. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(Aug (9587)):580-589.
41. Roman F., Clement F., Dewe W., Walravens K., Maes C., Willekens J., et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. ClinVaccine Immunol 2011, 18(5):835.
42. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(Jun (9272)):1937-1943.
43. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424.
44. Eichelberger M., Golding H., Hess M., Weir J., Subbarao K., Luke C.J., et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 2008, 26(Aug (34)):4299-4303.
45. Sasaki S., He X-S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008, 3(8):e2975.
46. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453(May (7195)):667.
47. Wrammert J., Koutsonanos D., Li G-M., Edupuganti S., Sui J., Morrissey M., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208(1):181.
48. Bodewes R., Kreijtz J.H., Baas C., Geelhoed-Mieras M.M., de Mutsert G., van Amerongen G., et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE 2009, 4(5):e5538.
49. Wagar L.E., Rosella L., Crowcroft N., Lowcock B., Drohomyrecky P.C., Foisy J., et al. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. PLoS ONE 2011, 6(11):e28063.
50. Brokstad K.A., Eriksson J.C., Cox R.J., Tynning T., Olofsson J., Jonsson R., et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 2002 Apr 1, 185(7):878-884.
51. Thompson M.G., McIntyre A.F., Naleway A.L., Black C., Kennedy E.D., Ball S., et al. Potential influence of seasonal influenza vaccination requirement versus traditional vaccine promotion strategies on unvaccinated healthcare personnel. Vaccine 2013, 31(Aug (37)):3915-3921.
52. Babcock H.M., Gemeinhart N., Jones M., Dunagan W.C., Woeltje K.F. Mandatory influenza vaccination of health care workers: translating policy to practice. Clin Infect Dis 2010, 50(Feb (4)):459-464.
53. Hollmeyer H., Hayden F., Mounts A., Buchholz U. Review: interventions to increase influenza vaccination among healthcare workers in hospitals. Influenza Other Respir Viruses 2013, 7(Jul (4)):604-621.